Abstract
Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija. Our clinical experience with omalizumab-treated severe allergic asthma patients are presented in this manuscript.Me tho ds: Severe asthma patients who have started tretment with omalizumab at our clinic from october 2007 to december 2011 were included in this study. Patients were treated with subcutaneus applications of omalizumab every 2 or 4 weeks, dosed according to body weight and baseline IgE. Outcome measures after one year of treatment were: pulmonary function measured as FEV1, ACT (athma control test) score, number of asthma exacerbations/year, the dose of methylprednisolone needed in regular asthma tretment, and side effects. Results: We included 15 patients with severe allergic asthma in the treatment with omalizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
